TITLE

India: Multi-national pharmaceutical company challenges patent law

AUTHOR(S)
Betteridge, Glenn
PUB. DATE
May 2007
SOURCE
HIV/AIDS Policy & Law Review;May2007, Vol. 12 Issue 1, p35
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the outcome of the implementation of India's Patents Act which was amended to bring India into compliance with its obligations under the World Trade Organization's (WHO) Agreement on Trade-Related Aspects of Intellectual Property Rights. The section was made to avoid evergreening where pharmaceutical companies can extend their monopoly on the sale of a medication.
ACCESSION #
25553560

 

Related Articles

  • A Detailed Study of Patent System for Protection of Inventions. TULASI, G. KRISHNA; RAO, B. SUBBA // Indian Journal of Pharmaceutical Sciences;2008, Vol. 70 Issue 5, p547 

    Creations of brain are called intellect. Since these creations have good commercial value, are called as property. Inventions are intellectual property and can be protected by patents provided the invention is novel, non-obvious, useful and enabled. To have fare trade among member countries,...

  • Trade Pact Weakens Patent Protections. Wechsler, Jill // Pharmaceutical Executive;Dec2001, Vol. 21 Issue 12, p24 

    Focuses on the impact on pharmaceutical companies of the World Trade Organization's decision to allow nations to override patent laws in 2001. Purpose of the decision; Details of the Trade-Related Aspects of Intellectual Property declaration; Implication of the decision for poor countries.

  • Research & Markets: China's Guidebook for Pharmaceutical Patent Protection.  // Biomedical Market Newsletter;5/15/2011, p185 

    The article focuses on China's Guidebook for Pharmaceutical Patent Protection. It states that overseas and multinational pharmaceutical companies might use the guidebook as a significant resource to obtain a successful patent protection for their intellectual property in China. Meanwhile, it...

  • Intellectual property theft is top risk for firms with operations in China. Gonzalez, Gloria // Business Insurance;3/26/2007, Vol. 41 Issue 13, p16 

    The article reports on intellectual property risks faced by multinational companies with operations in China. Based on a survey of China Association of Enterprises with Foreign Investment members, 10% have estimated revenue losses of more than 20% due to intellectual property violations. It is...

  • Intellectual property law in Israel, and US and European objections: Market exclusivity vs. data exclusivity. Morag-Sela, Tamar; Cohn, Ilan; Kowalski, Thomas J.; Jarecki-Black, Judy; Clyde-Watson, Zoe // Nature Biotechnology;Dec2004, Vol. 22 Issue 12, p1591 

    The article discusses issues related to intellectual property (IP) rights to pharmaceuticals in Israel. The country has a very strong generic pharmaceutical industry. Israel's past record of defending and respecting IP rights has led major companies around the world to file patent applications...

  • A "Calibrated Approach": Pharmaceutical FDI and the Evolution of Indian Patent Law. Linton, Katherine Connor; Corrado, Nicholas // Journal of International Commerce & Economics;Aug2008, Vol. I, p163 

    India has charted its own intellectual property (IP) path over the last 35 years, attempting to foster the growth of a domestic pharmaceutical industry and access to medicine while, more recently, also addressing the requirements of the international IP regime. Multinational companies (MNCs)...

  • Legal Aspects of Foreign Company Operations in China: Intellectual Property Rights in China. Desevedavy, Franck // Doing Business with China;2005, p93 

    Provides information on the intellectual property rights implemented in China. Intellectual property laws and regulations that were published when China acceded to the World Trade Organization from 1992 to 2002; Signs that cannot be used or registered as a trademark; Categories of patents that...

  • New deal from the World Trade Organisation. Pollock, Allyson M.; Price, David // BMJ: British Medical Journal (International Edition);9/13/2003, Vol. 327 Issue 7415, p571 

    Reports on the supposed resolution of the issue of giving poor countries access to essential medicines without breaching laws on intellectual property by the World Trade Organization (WTO). Past agreements; Allowance of drug companies to charge monopoly prices for essential drugs; Provisions for...

  • Patent policy and public health in developing countries: lessons from Japan. Aoki, Reiko; Kubo, Kensuke; Yamane, Hiroko // Bulletin of the World Health Organization;May2006, Vol. 84 Issue 5, p417 

    The article discusses on the implications of the World Trade Organization's Trade-Related Aspects of Intellectual Property Rights Agreement on the public health sector in developing countries. Under the product patent law, local pharmaceutical companies are restricted to copy manufactured drugs...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics